You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Arf6 inhibitors for the treatment of uveal melanoma

    SBC: NAVIGEN, INC.            Topic: 102

    DESCRIPTION provided by applicant Activating mutations in G proteins are the drivers of oncogenesis in numerous cancers Therefore identifying drugs that block the signaling pathways controlled by these mutations could have enormous therapeutic consequences Uveal melanoma is a prototypical G driven cancer in which about of tumors have activating mutations in one of two G encoding genes ...

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  2. Targeted drug delivery to tumor microenvironment

    SBC: SIBTECH, INC.            Topic: 102

    DESCRIPTION provided by applicant The goal of this project is to test the feasibility of targeted delivery of andquot re programmingandquot liposomal drugs to tumor associated macrophages TAMs TAMs are the major component of tumor microenvironment that generally supports tumor growth and interferes with anti tumor therapy These effects are significantly mediated by about of TAMs that ...

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  3. Profiling Circulating miRNA Without PCR for Early Detection of Pancreatic Cancer

    SBC: VAJRA INSTRUMENTS, INC.            Topic: 102

    DESCRIPTION provided by applicant Pancreatic cancer PaC has a poor prognosis in most cases due to the lack of early detection owing to its nonspecific asymptomatic nature An effective inexpensive screening tool is needed for early diagnosis within years of tumor initiation It is well accepted that genomic instability is a hallmark of cancer Recent research indicates that less than ...

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  4. Development of a heterologous bio-production system for the clinically important anti-cancer natural product compound ET-743

    SBC: ALLUVIUM BIOSCIENCES, INC.            Topic: 102

    DESCRIPTION provided by applicant Ecteinascidin ET is a tetrahydroisoquinolone natural product that displays potent anti cancer activity Isolated in very low yields from the marine colonial tunicate Ecteinascidia turbinata ET has been developed by PharmaMar as a cancer chemotherapeutic agent currently marketed in Europe as trabectedin Yondelis r for the treatment of soft tiss ...

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  5. Novel Compounds from Sycamore Leaves for the Treatment of MRSA

    SBC: Twenty First Century Therapeutics, Inc.            Topic: R

    DESCRIPTION provided by applicant Methicillin resistant staphylococcus aureus MRSA is a serious pathogen that can cause patient mortality and extend hospital stays resulting in higher health care costs Currently over of staph cases around the world are caused by MRSA In recent years MRSA has evolved into several resistant strains that can resist to multiple antibiotics such as penic ...

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  6. Expanding the throughput of real-time toxicological screening of cardiac differentiation by expressing a synthetic luciferase/luciferin genetic pathway in iPSCs

    SBC: 490 BIOTECH INC            Topic: NIEHS

    DESCRIPTION provided by applicant Expanding the throughput of real time toxicological screening of cardiac differentiation by expressing a synthetic luciferase luciferin genetic pathway in iPSCs Project Summary This Small Business Innovation Research SBIR Phase I project proposes to develop autonomously bioluminescent induced pluripotent stem cells iPSCs for continuous reagent free and ...

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. Targeted Intraceptor Nanoparticle for Macular Degeneration

    SBC: Iveena Delivery Systems, Inc.            Topic: N

    DESCRIPTION provided by applicant Age related macular degeneration AMD is a leading cause of blindness in United States and many other industrialized nations There are two types of AMD the andquot dryandquot and andquot wetandquot forms Dry AMD is a chronic disease that usually causes variable degree of visual impairment In contrast in wet AMD which affects of AMD patients t ...

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. A multi-analyte device for air quality monitoring

    SBC: TF HEALTH CORPORATION            Topic: NIEHS

    DESCRIPTION provided by applicant Air quality affects the health and well being of each of us especially those with chronic respiratory diseases Acute exposure to fatal levels of hazard materials causes millions of accidents every year and unnoticed long term exposure to lower levels of chemicals affect far more people Various technologies have been developed to monitor air quality but no ...

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  9. Isolation and Characterization of Low Molecular Weight Compounds Derived from Plant Extracts that Activate the IRS-2 Dependent Insulin Signaling Cascade.

    SBC: HOUSEY PHARMACEUTICAL RESEARCH LAB            Topic: 200

    DESCRIPTION provided by applicant This is a Phase I SBIR Application entitled andquot Isolation and Characterization of Low Molecular Weight Compounds Derived from Plant Extracts that Activate the IRS Dependent Insulin Signaling Cascade andquot Diabetes is a growing and significant global health concern Insulin Receptor Substrate IRS is a critical component in the insulin mediated s ...

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  10. The anti-diarrheal potential of a LPA analog Rx100

    SBC: Rxbio, Inc.            Topic: 300

    DESCRIPTION provided by applicant Secretory diarrhea is a leading cause of death worldwide among children under the age of five Its pathology involves cystic fibrosis transmembrane conductance regulator CFTR which provides a primary pathway for Cl secretion Targeting CFTR to prevent reduce losses of electrolytes and water is a therapeutic strategy Lysophosphatidic acid LPA a naturally o ...

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government